anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A detailed research will be conducted on nearly 100 patients after ethical approval from the Ethical Review Board of Riphah International University Faisalabad Campus. A total of 100 patients with Anterior Cruciate Ligament injuries will be selected from different areas of community and rehabilitation centers. Informed consent will be taken from each patient. The tool will be used three times in the same Pakistani population with Anterior Cruciate Ligament injuries to check inter and intra-observer reliability of the final Urdu-LKS. The Lysholm questionnaire translation will be carried out in 6 steps by the guidelines of the early researches and the Consensus-based Standards for the selection of health Measurement Instruments standard. Statistical Package of Social Sciences 23 will be employed to do data analysis.
The mammography management system can provide for quality control of devices associated with the system. A method is provided for monitoring the quality standards of a mammography facility. The method can comprise generating a report that analyzes information collected in preselected data fields on the performance of a resource after automatically executing a quality control test plan configured for the resource at a preselected time. The quality control test plan is configured based on resource type. 
     A method can provide for monitoring the quality of exams performed on a plurality of patients. The method comprises generating a report automatically analyzing and organizing information collected on the accuracy of exams preformed on the plurality of the patients into statistics. These statistics can compare the information based on a radiologist or a facility with other radiologists other facilities or overall statistics for a plurality of radiologists or a plurality of facilities.
Patients will receive a single dose of saline solution via the nasogastric tube at 24 hours after admission for small bowel obstruction. The volume of saline solution will be proportional to the volume of Gastrografin patients of similar weight and age would receive.
Geriatric patients are at increased risk for developing severe tendon disorders including tendon rupture when being treated with a fluoroquinolone such as ofloxacin. This risk is further increased in patients receiving concomitant corticosteroid therapy. Tendinitis or tendon rupture can involve the Achilles, hand, shoulder, or other tendon sites and can occur during or after completion of therapy; cases occurring up to several months after fluoroquinolone treatment have been reported. Caution should be used when prescribing ofloxacin to elderly patients especially those on corticosteroids. Patients should be informed of this potential side effect and advised to discontinue ofloxacin and contact their healthcare provider if any symptoms of tendinitis or tendon rupture occur (see Boxed Warning; WARNINGS; and ADVERSE REACTIONS, Postmarketing Adverse Event Reports).  
In phase 2/3 clinical trials with ofloxacin, 688 patients (14.2%) were ≥ 65 years of age. Of these, 436 patients (9%) were between the ages of 65 and 74 and 252 patients (5.2%) were 75 years or older. There was no apparent difference in the frequency or severity of adverse reactions in elderly adults compared with younger adults. The pharmacokinetic properties of ofloxacin in elderly subjects are similar to those in younger subjects. Drug absorption appears to be unaffected by age. Dosage adjustment is necessary for elderly patients with impaired renal function (creatinine clearance rate ≤ 50 mL/min) due to reduced clearance of ofloxacin. In comparative studies, the frequency and severity of most drug-related nervous system events in patients ≥65 years of age were comparable for ofloxacin and control drugs. The only differences identified were an increase in reports of insomnia (3.9% vs. 1.5%) and headache (4.7% vs. 1.8%) with ofloxacin. It is important to note that these geriatric safety data are extracted from 44 comparative studies where the adverse reaction information from 20 different controls (other antibiotics or placebo) were pooled for comparison with ofloxacin. The clinical significance of such a comparison is not clear(see CLINICAL PHARMACOLOGYand DOSAGE AND ADMINISTRATION).  
Elderly patients may be more sensitive to drug-associated effects on the QT interval. Therefore, precaution should be taken when using ofloxacin with concomitant drugs that can result in prolongation of the QT interval (e.g. Class IA or Class III antiarrhythmics) or in patients with risk factors for torsade de pointes (e.g. known QT prolongation, uncorrected hypokalemia)(See PRECAUTIONS, General, Torsade de pointes).  
  
Epidemiologic studies report an increased rate of aortic aneurysm and dissection within two months following use of fluoroquinolones, particularly in elderly patients [see Warnings].
The invention discloses a nimodipine solid dispersant and tablet and their preparation methods. The preparation method of the nimodipine solid dispersant comprises the following steps of blending nimodipine, polyvinylpyrrolidone and a volatile organic solvent to obtain a uniform mixed solution, uniformly spraying the mixed solution to a filler by a fluidized bed under the conditions of atomization pressure of 1.2-3.0bar, a liquid spraying rate of 3-12g/min, an inlet air temperature of 20-80 DEG C and an inlet air amount of 20-80m<3>/h, and carrying out granulation and drying, wherein a mass ratio of nimodipine to polyvinylpyrrolidone is 1: (1-6) and a mass ratio of nimodipine to the filler is 1: (2-15). The preparation method of the nimodipine solid tablet comprises carrying out raw material drying, adding accessory materials into the dried raw materials and carrying out tabletting. The preparation methods have simple processes. Preparation processes of the solid dispersant and tablet can be carried out simultaneously. The nimodipine solid dispersant particles have uniform particle size distribution, high solubility, good stability and high bioavailability.
BACKGROUND: Opioid-induced constipation (OIC) is the most prevalent side effect of methadone maintenance therapy (MMT). Naloxone could reduce the OIC.
METHOD: Fifty-six MMT cases (< 75 mg/day methadone, > 3 months) were entered randomly into four groups of a trial. They received placebo or naloxone tablets (0.5, 2, or 4 mg/day) once a day for 2 weeks. They continued their conventional laxative. Their constipation and opiate withdrawal (OWS) were evaluated by the Bristol Stool Form Scale (stool consistency and frequency), Patient Assessment of Constipation Symptoms (PAC-SYM) questionnaire, Constipation Scoring System (CSS), and the Subjective Opiate Withdrawal Scale (SOWS) before starting treatment and at the end of the first and second weeks.
RESULTS: The dose of 4 mg/day naloxone was excluded from the study due to severe OWS. The precipitants of groups had similar ages, methadone dose and duration, laxative use, and constipation scores at the start of the trial. However, 2 mg of naloxone could change the stool consistency (PV = 0.0052) and frequency (P = 0.0133), 0.5 mg/day dose only improved the stool consistency (P = 0.0016). The patients' CSS and PAC-SYM scores were reduced by naloxone after the 1st week of treatment. However, there was no significant difference in the mean score of SOWS at different assessment times and groups. Also, 3 and 4 cases of 0.5 and 2 mg/day groups, respectively, withdrew from the study due to OWS.
CONCLUSION: Oral naloxone at doses of 0.5 and 2 mg/day was significantly more effective than placebo on OIC in MMT. However, the dose of 4 mg induced intolerable OWS.
Based on pharmacokinetic studies with oral paliperidone, no dosage adjustment of INVEGA HAFYERA is required when administered concomitantly with valproate [see Clinical Pharmacology (12.3)] . Additionally, no dosage adjustment is necessary for valproate when co-administered with INVEGA HAFYERA [see Clinical Pharmacology (12.3)] . 

Pharmacokinetic interaction between lithium and INVEGA HAFYERA is unlikely.

Paliperidone is not expected to cause clinically important pharmacokinetic interactions with drugs that are metabolized by cytochrome P450 isozymes. In vitrostudies indicate that CYP2D6 and CYP3A4 may be involved in paliperidone metabolism; however, there is no evidence in vivothat inhibitors of these enzymes significantly affect the metabolism of paliperidone. Paliperidone is not a substrate of CYP1A2, CYP2A6, CYP2C9, and CYP2C19; an interaction with inhibitors or inducers of these isozymes is unlikely [see Clinical Pharmacology (12.3)].
This study is a cohort study that aims to explore the effects of different antihypertensive regimens on aortic remodelling in patients after aortic surgery by collecting the hospitalization and outpatient follow-up data. The study plans to gather perioperative and postoperative follow-up data from over 600 patients who underwent aortic surgery at the Eighth Affiliated Hospital and Beijing Anzhen Cardiothoracic Surgery Center. Patients were assigned based on the postoperative antihypertensive medication regimens. Datas was collected to compare the cardiovascular-related prognoses.

This study primarily includes patients who take oral antihypertensive medications after aortic surgery. The main observations will focus on postoperative complications related to the aorta (such as death, reoperation, dilation, etc.) and aortic diameters after the administration of different antihypertensive medications. Multivariate regression analysis will be employed to investigate the impact of different antihypertensive regimens on patients after aortic surgery.
A service actions database stores credentials for performing respective service actions. A service engineer (SE) database stores credentials of respective SE's. In a method of authorizing a servicing session of a medical device, a service ticket to perform a servicing session of the medical device is received. Credentials of a candidate SE are retrieved from the SE database. One or more service actions are determined for resolving the service ticket. Credentials required to perform the servicing session are retrieved from the service actions database based on the determined one or more service actions. It is determined whether the credentials of the candidate SE satisfy the credentials required to perform the servicing session. An indication is output that the candidate SE is unqualified to perform the servicing session when the credentials of the candidate SE do not satisfy the credentials required to perform the servicing session.
Patients in group 3 will receive motor sparing knee blocks with 0.5% ropivacaine with 1 µg/Kg of dexmedetomidine, 30 mg of ketorolac and 10 mg of morphine with a total local anesthetic volume of 60 ml (300 mg). Patients in group 3 will receive sham injections of saline (100 ml) periarticularly at the end of surgery.
The invention relates to a compressed air inhaler for the pulmonary application of a liposomal powder aerosol that carries active agents or is uncharged. The aim of the invention is to provide an inhaler by means of which the pulmonary application of especially liposomes that carry active agents is possible without forced breathing manoeuvres and by means of which the active agent can be transferred to the desired place of action in a sufficient amount without the active agent escaping. To this end, said compressed air inhaler comprises a receptacle (20) for the aqueous dispersion of liposomes. The liposomes carrying the active agents are dispersed in water in said receptacle. The receptacle is connected to an anatomising nozzle (1) and to a drying unit (17) via a device that doses liquids (19), whereby the drying unit can be an atomising chamber for spray drying the liposomes. An outlet (18) and a mouth piece are joined to said drying unit. The anatomising nozzle (1) is provided with separate supply channels (14, 16) for the compressed air and the dispersion of the liposomes (fig.1). The invention also relates to a novel powder aerosol consisting of liposomes or nanoparticles.
PROBLEM TO BE SOLVED: To obtain a hair growth agent capable of adjusting good environments for the production of hair, directly carrying in active ingredients into hair-matrix cells and hair roots, activating the respective functions and imparting sure effects on hair growth and hair production and simultaneously having hair care and skin care effects by promoting the washing of skin pores and the activity of the scalp in order to exhibit hair growth effects by a hair growth agent consisting essentially of only a natural ingredient and enhance safer and surer hair increasing effects. SOLUTION: The hair growth agent and skin care oil are obtained by extracting an active ingredient contained in Citrus unshu Marc. with a carrier oil as a solvent. The carrier oil containing the active ingredient is applied to an affected part and the whole to conduct massage. Thereby, not only skin is stimulated but also subcutaneous cells are activated and the aging of cells is suppressed to thereby restore the secretion of hormones to the normal state. As a result, hair-matrix cells can be activated to impart the vitality to hair papillae or hair roots.
In cases in which metabolic syndrome and non-alcoholic fatty liver are risk factors of obstetric complications, such as gestational diabetes (GDM) or preeclampsia (PE), we are able to offer systematic clinical results from determining the independent risk factor and developing a predictable model. Recently, obstetric complications, especially GDM and PE, have increased due to the growth of elder pregnancy. In addition, as liver dysfunction has been known to be an independent risk factor of diabetes, cardiovascular disease, high blood pressure and renal dysfunction, its clinical importance has risen. Metabolic syndromes, such as obesity, hypertension, type II diabetes and abnormal lipid profile, have been known for its importance in development of non-alcoholic fatty liver disease. Considering abnormal liver function being an independent risk factor of diabetes, cardiovascular disease, high blood pressure and renal dysfunction in normal adult patients, we are able to predict that liver dysfunction might be a high risk factor of obstetric complications in pregnant women. In previous studies, the frequency of liver dysfunction in normal pregnant women was obtained.

The purpose of this current study was to investigate the prevalence of metabolic syndrome, abnormal liver function and non-alcoholic fatty liver in early pregnancy and the related risks of obstetric complications.
OBJECTIVE: Bone marrow aspiration and lumbar puncture are procedures frequently performed in pediatric oncology. We aimed at assessing the incidence and risk factors of perioperative complications in children undergoing these procedures under sedation or general anesthesia.
METHODS: Based on the APRICOT study, we performed a secondary analysis, including 893 children undergoing bone marrow aspiration and lumbar puncture. The primary outcome was the incidence of perioperative complications. Secondary outcomes were their risk factors.
RESULTS: We analyzed data of 893 children who underwent 915 procedures. The incidence of severe adverse events was 1.7% and of respiratory complications was 1.1%. Prematurity (RR 4.976; 95% CI 1.097-22.568; P = 0.038), intubation (RR: 6.80, 95% CI 1.66-27.7; P =0.008), and emergency situations (RR 3.99; 95% CI 1.14-13.96; P = 0.030) increased the risk for respiratory complications. The incidence of cardiovascular instability was 0.4%, with premedication as risk factor (RR 6.678; 95% CI 1.325-33.644; P =0.021).
CONCLUSION: A low incidence of perioperative adverse events was observed in children undergoing bone marrow aspiration or lumbar puncture under sedation and/or general anesthesia, with respiratory complications being the most frequent. Careful preoperative assessment should be undertaken to identify risk factors associated with an increased risk, allowing for appropriate adjustment of anesthesia management.
PURPOSE: To provide an interface coating technique for inexpensive, stable and practicable iontophoresis by forming a surface coating layer of an ionic surfactant on a medicine holding member, thereby additionally enhancing the efficiency of utilizing a physiologically active peptide based medicine. CONSTITUTION: Two polyethylene cups 9, 9' are arranged in the upper part of a base 10 having resilience and hardness. A medicine dissolving liquid 7 consisting of distilled water for injection etc., is stored in the cup 9' to form a reservoir 12. A conductive gel 3 is built in the cup 9. The lower part of the cup 9 is provided with a hole 14, and further, an ion exchange membrane 4, a non-woven fabric 5 and a porous nylon body 6 are arranged in lamination therein to form an applicator 13. The ion exchange membrane 4, the non-woven fabric 5 and the porous nylon body 6 are treated by uniformly coating or impregnating these medicine holding members with an aq. benzalkonium chloride soln. and are dried by draining.
Acquisition of a hyperdiploid (HY) karyotype or immunoglobulin heavy chain (IgH) translocations are considered key initiating events in multiple myeloma (MM). To explore if other genomic events can precede these events, we analyzed whole-genome sequencing data from 1173 MM samples. By integrating molecular time and structural variants within early chromosomal duplications, we indeed identified pregain deletions in 9.4% of patients with an HY karyotype without IgH translocations, challenging acquisition of an HY karyotype as the earliest somatic event. Remarkably, these deletions affected tumor suppressor genes (TSGs) and/or oncogenes in 2.4% of patients with an HY karyotype without IgH translocations, supporting their role in MM pathogenesis. Furthermore, our study points to postgain deletions as novel driver mechanisms in MM. Using multiomics approaches to investigate their biologic impact, we found associations with poor clinical outcome in newly diagnosed patients and profound effects on both the oncogene and TSG activity despite the diploid gene status. Overall, this study provides novel insights into the temporal dynamics of genomic alterations in MM.
In the previous few years, agreat evidence has established for efficiency of dexmedetomidine (DEX) in management of TBI. Dexmedetomidine is a highly selective alpha-2 receptor agonist, its major sympatholytic and sedative actions are mediated primarily via reduced transmission in the locus coeruleus which is a part of the reticular activating system. It provides excellent sedation without respiratory depression, ease of arousability, and need not be stopped during weaning the patient from mechanical ventilation or for neurological assessment. It suits as an ideal sedative agent for patients with TBI. DEX has been shown to reduce cerebral ischemia/ reperfusion injury by suppressing inflammation, activating the anti-apoptotic signaling pathways, and inhibiting neuronal autophagy. Animal studies have shown that alpha-2 agonists are neuroprotective in craniocerebral and subarachnoid injuries but this has not been definitively shown in humans . The efficacy of DEX for sedation in intubated ICU patients is well established; however, its use in patients with TBI has not been comprehensively described .

Magnesium has shown great promise as a potential therapeutic agent in TBI during animal experiments . Magnesium is essential for the maintenance of cell membrane integrity, the stabilisation of genetic material and for a number of fundamental enzymatic reactions such as glycolysis, oxidative phosphorylation and protein synthesis, it is also known to act presynaptically to inhibit the release of excitatory amino acids, and be a non-competitive inhibitor of the voltage-gated N-methyl-D-aspartate (NMDA) receptor, an important link in the excitotoxic phase of secondary brain injury. As a consequence, magnesium's role in TBI has been of great interest to researchers.
BACKGROUND: Dynamic spasticity (DS) is a common complication post-spinal cord injury (SCI), marked by intermittent increases in muscle tone during postural transitions or movement. Despite its prevalence, high-quality research on DS incidence, risk factors, and underlying mechanisms in SCI patients remains limited. With the growing application of spinal cord stimulation (SCS) for spasticity control, the role of proprioception in DS development has garnered attention. Additionally, advances in diffusion tensor imaging (DTI) allow for the analysis of the reticulospinal tract's (RST) role in postural control among SCI patients. However, the impact of microstructural changes in RST and proprioception on DS following SCI remains unclear.
OBJECTIVE: To investigate the relationship between microstructural changes in the RST and proprioceptive circuits in SCI patients, exploring their association with DS and potential predictive factors that influence recovery.
METHODS: This is a 12-month prospective cohort study. The neurophysiological and global functional status of the participants will be assessed. Primary outcomes include DTI indices of RST and proprioception, and spasticity assessment. Secondary outcomes include auditory startle reflex (ASR), H-reflex, shear wave velocity (SWV), overall functional status including spinal cord independence measure, gait analysis, modified Barthel Index, and the 36-item short form health survey. Data will be collected at 1, 3, 6, and 12 months after enrolment. Matched healthy controls will be measured during the same period after recruitment.
DISCUSSION: This study is the first to explore the role of microstructural changes in the RST and proprioception in the assessment and prediction of DS following SCI. The findings aim to enhance theoretical understanding of SCS in spasticity management and to establish pre-treatment criteria for SCS interventions targeting motor function recovery in SCI.
TRIAL REGISTRATION NUMBER: ChiCTR2400090724.
Infants with congenital heart disease (CHD) are a low frequency but high acuity and stress population in the pediatric hospital setting. There are approximately 300 patients admitted a year that require cardiac surgery and are under the age of 6 months at Children's Mercy. These patients may spend less time in the hospital, but the care they require is often complex resulting in potential hemodynamic changes and pain responses for the infants. Smart technologies are used in CHD populations like single ventricle interstage monitoring at home, CHAMP App, but there are opportunities for baby-parent-nurse in-hospital smart solutions such as the SNOO Smart Sleeper bassinet by Happiest Baby INC . The SNOO Smart Sleeper has been used in more than 20 other hospitals across the country, including The University of Kansas Health System, mainly for infants related to preterm or neonatal abstinence syndrome (NAS). The SNOO utilizes some of the components of the 5 S's (swaddling, side/stomach position, shushing, swinging, and sucking) to aid as physical interventions for infant pain. This has been shown to be effective for pain reduction and less crying time after painful procedures . The calming response for infants has been seen to improve with soothing of the infant through supine mechanical movement, swaddling, and sound . A prospective observational cohort of preterm (32-36 weeks GA) neonates found that intermittent hypoxia and bradycardia significantly declined after use of womb-like soothing sound. The auditory neural pathways have close anatomical connection to the autonomic nervous system and the potential for auditory to parasympathetic response and reduced cardiac and respiratory rates are intriguing for evaluation in the infant population after cardiac surgery. The SNOO has yet to be used in the post-operative pediatric CHD population in the inpatient setting. The success in other fragile infant populations lends to a possible new area for use in the high risk CHD population in the post-operative recovery phase related to pain and hemodynamic changes.